anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology. SUBSTANCE: invention relates to polypeptide that is excreted by kidney, it doesn't comprise Fc-region of IgG in the parent form and can be used in medicinal practice. The parent polypeptide is modified by such manner in order to incorporate the saving receptor-binding epitope of Fc-region of IgG and to increase its circulatory half-life value. The modified polypeptide comprises amino acid sequence of Ig-domain or Ig-like domain that is not CH 2 -domain and amino acid sequence of the saving receptor-binding epitope of Fc-region of IgG located in the range of Ig-domain or Ig-like domain. Amino acid sequence of the modified polypeptide shows at least 70% of similarity with that of the parent polypeptide. Invention discloses method for preparing indicated polypeptide using DNA (in vector construction) encoding indicated polypeptide. Prepared polypeptide can be used for treatment of LFA-1-mediated impairment in mammals, among them, in humans also. Invention provides increasing half-life value of polypeptide that results to the enhancement of effectiveness of treatment. EFFECT: improved preparing method, valuable medicinal properties of polypeptide. 25 cl, 3 tbl
Ninety percent of patients who suffer from Hereditary Hemorrhagic Telangiectasia (HHT) experience epistaxis which can range from mild to recurrent, severe, life threatening episodes. Current methods to treat significant epistaxis have limitations, namely the need for general anesthesia and repeated treatments. The objective of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate (STS), for recurrent epistaxis related to HHT.

Sclerotherapy is the treatment of vascular lesions by injection with an agent which causes thickening of the vessel wall, obstruction of blood flow, clot formation and collapse of the lesion. Sclerotherapy is an established treatment modality for vascular malformations in the skin, GI tract, genitourinary tract and has been used for lesions in various sites in the head and neck. STS is an anion surfactant (detergent) that is commonly used for sclerotherapy. There are case reports in the literature describing sclerotherapy treatments for epistaxis related to HHT using other agents, but these case reports did not lead to prospective studies. We have performed a pilot study to analyze the tolerability and effectiveness of sclerotherapy with STS in a series of patients with recurrent epistaxis related to HHT. In our series, the treatment was found to be well tolerated and effective, based on patient administered questionnaire and review of clinical data. No complications related to the procedure were noted. Further prospective studies would help elucidate the role of sclerotherapy with STS in the treatment algorithm for recurrent epistaxis related to HHT.

Our goal is to conduct a prospective, randomized-controlled trial to test the efficacy and tolerability of sclerotherapy using STS in the treatment of recurrent epistaxis due to HHT. A modified crossover design will be utilized with the intervention group receiving sclerotherapy, plus any additional, previously utilized standard treatment methods needed to control epistaxis. The control group will receive their current standard treatment methods, followed by delayed intervention with sclerotherapy. The primary outcomes will be frequency and severity of epistaxis. Secondary endpoints will be hemoglobin level, tolerability of treatment, additional treatment requirements, and quality of life.
Each modality of prostate cancer treatment has the propensity to lead to negative outcomes on quality of life to varying degrees. It is our responsibility to incorporate into our practices the most beneficial treatment regimens that render patients' cancer-free while minimizing potential treatment-related adverse outcomes, including incontinence and erectile dysfunction. Urinary incontinence and erectile dysfunction are the two most well described complications of radical prostatectomy with observed rates of 8.4% and 59.9%, respectively. Delayed recovery of urinary continence following radical prostatectomy (RP) is a well-known entity. Numerous contributing factors have been identified for post-prostatectomy incontinence (PPI), including both patient (age, body mass index, membranous urethral length, prostate volume, pre-existing lower urinary tract symptoms, and oncologic factors) and surgeon characteristics (experience, technique).

In a systematic review a meta-analysis using a no pad or a single safety pad definition, Ficcara and colleagues showed that the 12-month urinary incontinence rates can range from 8% to 11%. As such, several reconstructive options have been incorporated into the contemporary RP to attempt to improve these outcomes. The anatomy of urethral-sphincteric vesico-prostatic complex is well-described, leading to attempts to perform reconstruction of the Denonvilliers' musculofascial plate during the urethrovesical anastomosis (UVA) at the time of RP. Performing a posterior reconstruction (PR) of the rhabdosphincter was first reported by Rocco et al. in 2006 during open retropubic RP, showing a 3, 30, and 90-day improvement in urinary continence post catheter removal.

Posterior reconstruction urethrovesical anastomosis (PR-UVA) has been hypothesized to improve the integrity of the rhabdosphincter and potentially increase the functional urethral length. However, a recent systematic review evaluating the efficacy of PR-UVA showed no improvement in urinary continence at 1 week and 3, 6, and 12 months. Conflicting studies within the literature render an environment of clinical equipoise in this specific patient-related outcome. Our study objective was to address the true clinical benefit of the PR-UVA in a large prospective randomized controlled trial (RCT).
Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their normal left ventricular diastolic function.
An approach is provided for managing clinical trials and research. The approach involves collecting, in real-time, trial data from a plurality of data sources corresponding to a plurality of clinical trials. The approach also involves receiving, via a graphical user interface, input data specifying a medical indication. The approach further involves aggregating the trial data from the plurality of data sources based on the input data, and selecting one or more of the plurality of clinical trials based on the input data. The approach also involves determining a plurality of metrics for the selected one or more of the clinical trials. The approach further involves generating performance evaluation data for the selected one or more of the clinical trials using the plurality of metrics; and outputting, in real-time, the performance evaluation data for presentation via the graphical user interface.
INTRODUCTION: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. Therefore, consideration of the impact of treatment on HRQoL in addition to clinical outcomes is vital.
PATIENTS AND METHODS: In the phase I/II MajesTEC-1 (NCT03145181, NCT04557098) study, patients with RRMM who received teclistamab, an off-the-shelf, T-cell redirecting BCMA × CD3 bispecific antibody, had deep and durable responses with manageable safety. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30-item and the EuroQol 5 Dimension 5 Level descriptive questionnaire. Changes over time from baseline were measured with a repeated measures mixed-effects model. Proportions of patients with clinically meaningful improvement after starting treatment and time to clinically meaningful worsening were assessed.
RESULTS: Compliance was maintained throughout the study. Compared with baseline, positive changes were observed for pain, global health status, and emotional functioning with treatment; other assessments were largely unchanged from baseline. Post hoc analysis showed patients with deeper clinical response generally reported improved HRQoL outcomes. Following an initial decline in HRQoL in some scales, the proportion of patients reporting clinically meaningful improvements increased, while the proportion reporting clinically meaningful worsening decreased over time. Clinically meaningful improvements in pain were reported in ≥40% of patients at most assessment time points.
CONCLUSIONS: These results complement previously reported clinical benefits and support teclistamab as a promising therapeutic option for patients with RRMM.
In 1996, Goggins and colleagues demonstrated the importance of germline BRCA2 pathogenic variants in the development of apparently sporadic pancreatic ductal adenocarcinoma (PDAC). Previously, the group identified homozygous deletion of the 13q region in PDACs, enabling the identification of the BRCA2 gene. This 1996 article first revealed loss of BRCA2, both germline and somatic, as a key driver of PDAC at a time when there was still doubt if PDAC even had an inherited component. Contrary to the prevailing wisdom, not all individuals with inherited pathogenic BRCA2 variants had a family history of cancer. The innovative bedside-to-bench nature of this work revealed that individuals with these variants would be missed if genetic testing was limited only to those meeting the family history criteria. Therefore, Goggins and colleagues advocated that universal genetic testing may be indicated for pancreatic cancer at a time when genetic testing was in its infancy. Twenty-three years later, in 2019, universal testing for pancreatic cancer became standard of care in the United States. Additionally, this work and future-related publications by the Kern Laboratory set the stage for targeting BRCA2 and related DNA repair mutations in pancreatic cancer via a synthetic lethal therapeutic approach. The provocative discussion initiated by this team in this publication is still inspiring the field today. In this seminal publication, Goggins and colleagues profoundly impacted the direction of pancreatic cancer research, leading to a more sophisticated approach to designing earlier detection and precision treatment strategies for pancreatic cancer. See related article by Goggins and colleagues, Cancer Res 1996;56:5360-4.
Children assigned to the virtual reality group received virtual balance training using Nintendo Wii and Wii Balance Board, with a custom training program developed from activities on the Wii Fit Plus game. Training was conducted for 30 minutes, 5 sessions/week for 2 successive weeks (total of 10 sessions). Two sessions with Wii Fit Plus were conducted before the treatment protocol to help the children familiarize with the VR setup. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
BACKGROUND: Consensus guidelines recommend ≥ 2 mm margins in patients undergoing partial mastectomy (PM) for ductal carcinoma in situ (DCIS). It is unknown whether the number or proximity of margins less than 2 mm is associated with an increased mastectomy rate in patients attempting breast conservation therapy (BCT) for DCIS. The aim of this study is to examine this relationship.
PATIENTS AND METHODS: An institutional database review identified 208 patients with DCIS who underwent PM at a tertiary referral center and community hospitals from July 2020 to June 2023. Patients with a history of breast cancer, previous surgery for breast cancer, ipsilateral invasive carcinoma, papillary carcinoma, Paget's disease, more lobular carcinoma in situ (LCIS) than DCIS present, initial mastectomy, no DCIS present, routine shave margins (of all vectors), and ≥ 2 mm margins of all six vectors were excluded. Selective intraoperative margin re-excisions were included.
RESULTS: A total of 208 patients who met inclusion criteria were retrospectively reviewed. 122 (25%) had one close/positive (< 2 mm) margin and 86 (18%) had two or more close/positive margins. Of the patients with one close/positive margin, 7% (9/122) eventually underwent mastectomy. Of the patients with two or more close/positive margins, 20% (17/86) eventually underwent mastectomy. Overall, no patients with opposing margins underwent mastectomy.
CONCLUSIONS: Patients undergoing PM for DCIS have a mastectomy rate that is increased threefold, with two or more close/positive margins at initial PM, when compared with those with only one close/positive margin. The presence of opposing close/positive margins at initial PM did not increase the mastectomy rate and most were cleared with re-excision.
PROBLEM TO BE SOLVED: To provide a novel maillard reaction inhibitor.SOLUTION: The maillard reaction inhibitor comprises a phenylethanoid derivative represented by formula (I) or a salt thereof as an active ingredient. The maillard reaction inhibitor comprises a plant such as olive containing hydroxytyrosol or tyrosol, or an extract of the plant, as an active ingredient. Food and beverage containing collagen and the phenylethanoid derivative are also provided. The maillard reaction inhibitor exhibits a high maillard reaction inhibitory action, effectively suppresses production of AGEs and is thus capable of preventing and treating various symptoms induced by AGEs, for example, suppressing aging caused by the maillard reaction. The maillard reaction inhibitor is also capable of effectively preventing and treating diabetic complications. The food and beverage comprising collagen and the maillard reaction inhibitor are capable of inhibiting the maillard reaction in food and suppressing food deterioration, thereby keeping the quality thereof.
INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.
We will recruit 450 subjects ranging from 9 to 11 years old (or 3rd to 5th graders). These children who commute to school will perform repeated monthly measures of pulmonary function tests using spirometry, pulmonary inflammation via exhaled breath, and asthma symptoms and clinical encounters, up to 3 school years. These 500 children will represent 3 exposure scenarios: 1) one group of 125 children riding retrofitted school buses or private cars; 2) 250 children riding old buses who will change to retrofitted buses during the first or second year of the study; and 3) 125 children who ride old diesel buses through the study. All subjects will be either healthy or having physician-diagnosed asthma with severity ranging from mild intermittent to moderate persistent. Personal exposure monitoring of particulate matter, CO, NO2, and SO2 will be performed on a subset of 144 asthmatic subjects, with each subject being monitored for up to 2 days, in each monitoring year.

Subjects participating in the study will wear a small backpack containing several personal air monitors measuring real-time particulate matter concentrations and carbon monoxide concentrations as well as integrated (24 hour averaged) measurements of SO2 and NO2. The children's personal monitoring will begin when they wake up in the morning and continue for 24-hours. When wearing the backpack is inconvenient, such as when sleeping, the monitoring equipment should be placed in close proximity to the subject. Once the subject arrives at school, s/he will be asked to perform three respiratory tests: exhaled nitric oxide, exhaled breath condensate, and spirometry. At the end of the school day, the subject will be asked to perform the same two tests of lung function as earlier, plus an additional test of exhaled breath condensate. The subject will then continue his/her day as normal. A technician will replace the filter in the particulate matter monitor between 6 and 7 PM. We will repeat the same monitoring procedure the following morning when the subject wakes up for another 24-h. Monitoring will stop on the third morning when the subjects wake up. In addition to the personal monitoring, a monitoring kit will be installed in the subject's school bus and will be operated by a technician. This in-vehicle monitoring kit includes everything contained in the personal monitoring kit, plus a P-TRAK (TSI, model 8525) for real-time ultra-fine particle counts, two Harvard Personal Environmental Monitors (HPEM) with Teflon and quartz filters respectively for determining elemental carbon fractions, an EcoChem PAS2000CE monitor for polycyclic aromatic hydrocarbons (PAHs), and a global positioning system personal acquisition logger (GPS-PAL). The following timeline shows the typical daily schedule for a subject participating in the study.
INTRODUCTION: The ideal mesh type for hernia repair in a contaminated field remains controversial. Data regarding outcomes beyond 1 year and the impact on quality of life (QoL) are unknown. This study aims to evaluate the long-term surgical outcomes and patient-reported outcomes (PROs) after contaminated repair with poly-4-hydroxybutyrate (P4HB) mesh.
MATERIALS METHODS: Patients undergoing a contaminated hernia repair with P4HB between 2015 and 2020 were identified. Surgical site occurrences and hernia recurrences were recorded. Long-term PROs as defined by the Abdominal Hernia-Q and Hernia-Related Quality-of-Life Survey were assessed.
RESULTS: Fifty-five patients were included with a mean age of 54.5 years, a body mass index of 34 kg/m2, and a defect size of 356.9 ± 227.7 cm2. Median follow-up time was 49 months with a reoperation rate of 14.5% and a hernia recurrence rate of 7.3%. Of the 55 patients, 37 completed preoperative and postoperative PRO questionnaires. When comparing preoperative with postoperative Abdominal Hernia-Q, there was significant improvement in overall PROs (2.1 vs 3.5, P < 0.001). This improvement was maintained with no significant changes between postoperative scores over the course of 5 years. Patients with complications saw the same improvement in postoperative PRO scores as those without complications.
CONCLUSIONS: Our study found a low hernia recurrence and acceptable long-term reoperation rates in patients undergoing hernia repair with P4HB mesh in a contaminated setting. We demonstrate a sustained significant improvement in QoL scores after hernia repair. These data yield insight into the long-term outcomes and QoL improvement, providing physicians further knowledge to better counsel their patients.
PURPOSE: Gastroesophageal reflux disease (GERD) is an issue after one anastomosis gastric bypass (OAGB) and modification of OAGB with adding an anti-reflux system may decrease the incidence of postoperative GERD. This study aimed to compare the efficacy of the anti-reflux mechanism to treat preoperative GERD and prevent de novo GERD.
METHODS: A prospective randomized clinical trial study was conducted on patients with a body mass index of 40 and more from August 2020 to February 2022. Patients undergoing one anastomosis gastric bypass with and without anti-reflux sutures (groups A and B, respectively). These patients had follow-ups for one year after the surgery. GERD symptoms were assessed in all the patients using the GERD symptom questionnaire.
RESULTS: The mean age was 39.5 ± 9.8 years and 40.7 ± 10.2 years in groups A and B respectively. GERD symptoms remission occurred in 76.5% and 68.4% of patients in groups A and B, respectively. The incidence of de novo GERD symptoms was lower in group A, compared to group B (6.2% and 16.1% in groups A and B respectively), without any statistically significant difference (p-value: 0.239).
CONCLUSION: GERD symptoms and de novo GERD after OAGB seems to be under-reported after OAGB. This study suggests that applying an anti-reflux suture can decrease de novo GERD symptoms.
Use of an apoptosis-inducing and/or -stimulating substance (AIS) that interacts with mitochondrial potassium channels (MK) to prepare a composition for preventing and/or treating diseases associated with reduced apoptosis. Use of at least one apoptosis-inducing and/or -stimulating substance (AIS) to prepare a composition for prevention and/or treatment of human or animal diseases which involve (or are associated with) excessive reduction in apoptosis and/or, particularly, excessive cell growth and/or division, or in which targeted apoptosis of particular cells is sought. The new feature is that AIS acts by interaction with mitochondrial potassium channels (MK) of the cells concerned. An independent claim is also included for a method for discovery or identification of AIS. ACTIVITY : Parasiticide; Antibacterial; Virucide; Anti-HIV; Hepatotropic; Cytostatic; Apoptotic. No details of tests for these activities are given. MECHANISM OF ACTION : Blocking and/or inhibiting mitochondrial potassium channels; interaction with natural antiapoptotic substances.
BACKGROUND: The Asian Working Group for Sarcopenia (AWGS) introduced the concept of "possible sarcopenia" in 2019. However, the association between possible sarcopenia and hip fracture is not well characterized. Hence, we conducted a study to explore this association in older Chinese adults.
METHODS: This was a population-based cohort study based on nationally representative data from the China Health and Retirement Longitudinal Study. Individuals aged ≥60 years with no history of hip fracture at baseline (2011-2012) were included and followed up until September 2018. Possible sarcopenia was defined based on the AWGS 2019 criteria during the study period, and the occurrence of hip fractures was monitored. The association between possible sarcopenia and hip fractures was assessed using Cox proportional hazards regression models.
RESULTS: A total of 4,011 participants were included, of whom 44.8 % had possible sarcopenia. During the 7-year follow-up, 197 individuals experienced hip fractures. Individuals with possible sarcopenia had a significantly higher risk of hip fractures than those without possible sarcopenia (hazard ratio: 2.00, 95 % confidence interval: 1.46-2.75; P < 0.001). The association was consistently observed across various subgroups based on age, sex, and overweight status.
CONCLUSIONS: This study identified possible sarcopenia as a significant risk factor for hip fractures in older Chinese adults. These findings underscore the importance of addressing possible sarcopenia as a preventive measure to reduce the incidence of hip fractures.